Valerio Therapeutics Société anonyme (EPA:ALVIO)

France · Delayed Price · Currency is EUR

0.6900

-0.0160 (-2.27%)

Sep 11, 2026, 5:35 PM CET

Market Cap	344.62M +3,063.9%
Revenue (ttm)	2.57M +43.5%
Net Income	-4.90M
EPS	-0.02
Shares Out	499.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	160,835
Open	0.7060
Previous Close	0.7060
Day's Range	0.6870 - 0.7150
52-Week Range	0.0570 - 0.9800
Beta	2.06
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 26, 2026

About EPA:ALVIO

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody– drug conjugates, and chimeric antigen receptors. The company was formerly known as... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1997

Employees 25

Stock Exchange Euronext Paris

Ticker Symbol ALVIO

Full Company Profile

Financial Performance

In 2025, EPA:ALVIO's revenue was 2.57 million, an increase of 43.50% compared to the previous year's 1.79 million. Losses were -4.90 million, -79.53% less than in 2024.

Financial Statements